Breaking News, Collaborations & Alliances

Innovent and Lilly Partner to Bring Innovative Cancer Treatment to China

Sign a Distribution and Promotion Agreement in Mainland China regarding Lilly's non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca.

Author Image

By: Charlie Sternberg

Associate Editor

Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, and Eli Lilly and Company, have jointly announced a Distribution and Promotion Agreement in Mainland China regarding Lilly’s non-covalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor, Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets).   According to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters